
SurgMark
- Life Science & Healthcare
- Startup Stage
- Manufacturing
- B2B
- 2017
-
n/a
- Found
- Hamburg, DE
- surgmark.com
- SurgMark GmbH
-
Hamburg
About the company
SurgMark’s biopsy marker will become a standard diagnostic process, to mark breast cancer lesions prior to neoadjuvant therapy and surgery.
Our marker hits a growing market (CAGR 10%) with a volume of ~100 M $. FDA approval will be in 2021, sales in US starts in January 2022. Term sheet and LOI negotiations with strategic partners are ongoing. We are raising 950k EUR; closing is December 2019.
About the Team
Are you part of this team?Management

since 2019
Alumni
2017 - 2020 3 years, 0 months |
Peter Arthur Alexander Meier Geschäftsführer |
News about SurgMark
Recent mentions of SurgMark in podcasts & videos:
Jobs at SurgMark:
Other Startups nearby




FYI: English edition available
Hello my friend, have you been stranded on the German edition of Startbase? At least your browser tells us, that you do not speak German - so maybe you would like to switch to the English edition instead?
FYI: Deutsche Edition verfügbar
Hallo mein Freund, du befindest dich auf der Englischen Edition der Startbase und laut deinem Browser sprichst du eigentlich auch Deutsch. Magst du die Sprache wechseln?